BL22 Immunotoxin in Treating Patients With Refractory Chronic Lymphocytic Leukemia, Prolymphocytic Leukemia, or Non-Hodgkin's Lymphoma [clinicaltrials:NCT00126646]
BL22 Immunotoxin in Treating Patients With Refractory Chronic Lymphocytic Leukemia, Prolymphocytic Leukemia, or Non-Hodgkin's Lymphoma [clinicaltrials:NCT00126646]
Bio2RDF identifier
NCT00126646
Bio2RDF namespace
clinicaltrials
Bio2RDF uri
http://bio2rdf.org/clinicaltrials:NCT00126646
identifiers.org URI
anticipated enrollment [clinicaltrials_vocabulary:anticipated-enrollment]
authority [clinicaltrials_vocabulary:authority]
brief summary [clinicaltrials_vocabulary:brief-summary]
RATIONALE: BL22 immunot ...... a, or non-Hodgkin's lymphoma.
brief title [clinicaltrials_vocabulary:brief-title]
BL22 Immunotoxin in Treating P ...... mia, or Non-Hodgkin's Lymphoma
completion date [clinicaltrials_vocabulary:completion-date]
2009-06-01T00:00:00Z
condition [clinicaltrials_vocabulary:condition]
condition browse [clinicaltrials_vocabulary:condition-browse]
condition mesh [clinicaltrials_vocabulary:condition-mesh]
country [clinicaltrials_vocabulary:country]
detailed description [clinicaltrials_vocabulary:detailed-description]
OBJECTIVES:
- ...... study
within 1-2 years.
download date [clinicaltrials_vocabulary:download-date]
ClinicalTrials.gov processed this data on August 10, 2015
eligibility [clinicaltrials_vocabulary:eligibility]
firstreceived date [clinicaltrials_vocabulary:firstreceived-date]
2005-08-02T00:00:00Z
has expanded access [clinicaltrials_vocabulary:has-expanded-access]
intervention [clinicaltrials_vocabulary:intervention]
intervention browse [clinicaltrials_vocabulary:intervention-browse]
is fda regulated [clinicaltrials_vocabulary:is-fda-regulated]
is section 801 [clinicaltrials_vocabulary:is-section-801]
keyword [clinicaltrials_vocabulary:keyword]
B-cell chronic lymphocytic leukemia
Waldenstrom macroglobulinemia
extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
nodal marginal zone B-cell lymphoma
prolymphocytic leukemia
recurrent adult diffuse small cleaved cell lymphoma
recurrent grade 1 follicular lymphoma
recurrent grade 2 follicular lymphoma
recurrent mantle cell lymphoma
recurrent marginal zone lymphoma
lastchanged date [clinicaltrials_vocabulary:lastchanged-date]
2010-06-17T00:00:00Z
lead sponsor [clinicaltrials_vocabulary:lead-sponsor]
link [clinicaltrials_vocabulary:link]
location [clinicaltrials_vocabulary:location]
nct alias [clinicaltrials_vocabulary:nct-alias]
NCT00114751
nct id [clinicaltrials_vocabulary:nct-id]
NCT00126646
number of arms [clinicaltrials_vocabulary:number-of-arms]
official title [clinicaltrials_vocabulary:official-title]
Phase I Study of BL22, A Recom ...... c Leukemia and CD22+ Lymphomas
org study id [clinicaltrials_vocabulary:org-study-id]
CDR0000438672
overall official [clinicaltrials_vocabulary:overall-official]
overall status [clinicaltrials_vocabulary:overall-status]
oversight [clinicaltrials_vocabulary:oversight]
phase [clinicaltrials_vocabulary:phase]
primary completion date [clinicaltrials_vocabulary:primary-completion-date]
2009-03-01T00:00:00Z
responsible party [clinicaltrials_vocabulary:responsible-party]
secondary id [clinicaltrials_vocabulary:secondary-id]
NCI-05-C-0171
source [clinicaltrials_vocabulary:source]
start date [clinicaltrials_vocabulary:start-date]
2005-06-01T00:00:00Z
study design [clinicaltrials_vocabulary:study-design]
study type [clinicaltrials_vocabulary:study-type]
url [clinicaltrials_vocabulary:url]
verification date [clinicaltrials_vocabulary:verification-date]
2010-06-01T00:00:00Z
identifier
clinicaltrials:NCT00126646
title
BL22 Immunotoxin in Treating P ...... mia, or Non-Hodgkin's Lymphoma
@en
type
label
BL22 Immunotoxin in Treating P ...... a [clinicaltrials:NCT00126646]
@en